Alnylam Pharmaceuticals 认为，由于第一季度收入超出预期但每股收益不及预期，股权发生了变化。 Alnylam Pharmaceuticals sees stake shifts as Q1 revenue beats estimates but misses on EPS.

Meridian金融与永久有限公司减少了对Alnylam制药公司的股份,而Allspring全球投资控股公司则购买了股份。 Meridian Financial and Perpetual Ltd reduced their stakes in Alnylam Pharmaceuticals, while Allspring Global Investments Holdings purchased shares. Alnylam的股票被评为“Moderate Buy”,价格目标为337.91美元。 Alnylam's stock is rated "Moderate Buy" with a price target of $337.91. 该公司报告说,Q1收入为5.9419亿美元,超出预期,但错过了EPS的估计。 The company reported a Q1 revenue of $594.19 million, exceeding expectations, but missed EPS estimates. Alnylam的首席执行官最近还出售了她大部分股份。 Alnylam's CEO also sold a significant portion of her shares recently.